RUNX1 and acute lymphoblastic leukemia: The Outcomes Are Significantly Better for Final Low-Risk Patients Without ETV6-RUNX1 Positivity and Hyperdiploidy ALL Who Received Two Doses of Daunorubicin Compared With Those Receiving One Dose